|
|
 |
|
|
 |
|
 |
 |
Customized Laser Vision Treatment |
 |
|
|
|
|
Why we've chosen LADARVision®:
Using laser and radar technology developed by NASA, LADARVision® was the first approved system with active eye tracking, which compensates for involuntary eye movements. Although other laser systems have now developed eye-tracking systems, LADARVision® has the only system utilizing laser radar tracking technology, a system that measures eye movement 4,000 times each second and is capable of following eye movements regardless of how rapid or erratic they may be. Successful laser application does not rely on your ability to hold your eye perfectly still.
 |
 |
With tracker disabled the lines
show a high degree of
involuntary eye movement. |
With tracker enabled, the laser tracks
eye movement throughout the
procedure. |
LADARVision® is the only Excimer laser system with an FDA-approved claim that states that its LADARTrackerTM improves the accuracy of corneal shaping.
Many doctors believe that the LADARVision® system with its LADARTrackerTM is ideal for treating farsightedness and astigmatism because correction for these vision problems requires longer laser treatment times. During these longer treatments, the LADARVision® eye tracker accurately follows eye movement.
LADARVision® has the broadest range of approvals of any FDA-approved Excimer laser and makes it the only one capable of treating all types of refractive errors including nearsightedness, farsightedness and, astigmatism.
LADARVision®'s unique small-spot laser beam (less than one millimeter in diameter) offers micron size reshaping of the cornea resulting in an extremely smooth surface. LADARVision®'s ability to use a larger optical zone for treatments minimizes potential nighttime side effects of glare, halos, and starbursts. This feature is most important for patients with large pupils.
Contact our office at 877-LASIKNY to discover if CUSTOMCORNEA® can give you the vision that you have always wanted.
Back
Page 1 | Page 2 | Page 3 | Page 4 | Page 5
|
|
|
|
|
|
|
|
|
|
|
|
